PUBLISHER: TechNavio | PRODUCT CODE: 1516491
PUBLISHER: TechNavio | PRODUCT CODE: 1516491
The gastric cancer drugs market is forecasted to grow by USD 19489.6 mn during 2023-2028, accelerating AT a CAGR of 18.52% during the forecast period. The report on the gastric cancer drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness campaigns for gastric cancer, growing geriatric population, and increasing prevalence of gastric cancer .
Technavio's gastric cancer drugs market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 15.18% |
CAGR | 18.52% |
Incremental Value | $19489.6mn |
By Route Of Administration
By Distribution Channel
By Geography
This study identifies the increase in number of drug approvals and drug launches as one of the prime reasons driving the gastric cancer drugs market growth during the next few years. Also, strong pipeline of gastric cancer drugs and increasing R and D by vendors will lead to sizable demand in the market.
The report on the gastric cancer drugs market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastric cancer drugs market vendors that include Abbott Laboratories, AbbVie Inc., AROG Pharmaceuticals INC., AstraZeneca PLC, Bayer AG, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., DR Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd., Samsung Biologics Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Zydus Lifesciences Ltd.. Also, the gastric CANCER drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. IT presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: